100% Quality Guarantee
PhD-Level Technical Support
MOR106 Antibody - SDS-PAGE
Key Features

MOR106 Antibody (GXBS02713)

SKU GXBS02713
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Human
Reactivity Human
Applications ELISA, FCM, Functional assay
Isotype IgG1, kappa
$677 - $2,214

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

MOR106 Antibody

MOR106 Antibody is a research-grade biosimilar monoclonal antibody targeting Cytokine CX2. It is a human IgG1, kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry and functional assays. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.

Interleukin-17C (IL17C) is a ~21 kDa protein. Cytokine that plays a crucial role in innate immunity of the epithelium, including to intestinal bacterial pathogens, in an autocrine manner. Stimulates the production of antibacterial peptides and pro-inflammatory molecules for host defense by signaling through the NF-kappa-B and MAPK pathways. Acts synergically with IL22 in inducing the expression of antibacterial peptides, including S100A8, S100A9, REG3A and REG3G. Synergy is also observed with TNF and IL1B in inducing DEFB2 from keratinocytes. Depending on the type of insult, may have both protective and pathogenic properties, either by maintaining epithelial homeostasis after an inflammatory challenge or by promoting inflammatory phenotype.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose